148 related articles for article (PubMed ID: 28634107)
1. Chronic pramipexole treatment induces compulsive behavior in rats with 6-OHDA lesions of the substantia nigra and ventral tegmental area.
Dardou D; Reyrolle L; Chassain C; Durif F
Behav Brain Res; 2017 Aug; 332():327-336. PubMed ID: 28634107
[TBL] [Abstract][Full Text] [Related]
2. Reinforcing properties of Pramipexole in normal and parkinsonian rats.
Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO
Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.
Holtz NA; Tedford SE; Persons AL; Grasso SA; Napier TC
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():77-84. PubMed ID: 27216282
[TBL] [Abstract][Full Text] [Related]
4. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease.
Patricio F; Parra I; Martínez I; Pérez-Severiano F; Montes S; Aguilera J; Limón ID; Tizabi Y; Mendieta L
Neurotox Res; 2019 Apr; 35(3):699-710. PubMed ID: 30607904
[TBL] [Abstract][Full Text] [Related]
6. Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats.
Jiménez-Urbieta H; Gago B; Quiroga-Varela A; Rodríguez-Chinchilla T; Merino-Galán L; Delgado-Alvarado M; Navalpotro-Gómez I; Belloso-Iguerategui A; Marin C; Rodríguez-Oroz MC
Psychopharmacology (Berl); 2020 Aug; 237(8):2419-2431. PubMed ID: 32440779
[TBL] [Abstract][Full Text] [Related]
7. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Kemmerer ES; Desmond TJ; Albin RL; Kilbourn MR; Frey KA
Exp Neurol; 2003 Sep; 183(1):81-6. PubMed ID: 12957491
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
9. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
10. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Cole DG; Growdon JH; DiFiglia M
Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
[TBL] [Abstract][Full Text] [Related]
11. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Harkavyi A; Abuirmeileh A; Lever R; Kingsbury AE; Biggs CS; Whitton PS
J Neuroinflammation; 2008 May; 5():19. PubMed ID: 18492290
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.
Loiodice S; Winlow P; Dremier S; Hanon E; Dardou D; Ouachikh O; Hafidi A; da Costa AN; Durif F
Psychopharmacology (Berl); 2017 Jan; 234(1):15-27. PubMed ID: 27614895
[TBL] [Abstract][Full Text] [Related]
14. Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls.
Riddle JL; Rokosik SL; Napier TC
Behav Brain Res; 2012 Jul; 233(1):15-23. PubMed ID: 22727039
[TBL] [Abstract][Full Text] [Related]
15. Altered melatonin MT
Kang NH; Carriere CH; Bahna SG; Niles LP
Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
[TBL] [Abstract][Full Text] [Related]
16. Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine.
Ferraz AC; Xavier LL; Hernandes S; Sulzbach M; Viola GG; Anselmo-Franci JA; Achaval M; Da Cunha C
Brain Res; 2003 Oct; 986(1-2):200-5. PubMed ID: 12965246
[TBL] [Abstract][Full Text] [Related]
17. CART modulates the effects of levodopa in rat model of Parkinson's disease.
Upadhya MA; Shelkar GP; Subhedar NK; Kokare DM
Behav Brain Res; 2016 Mar; 301():262-72. PubMed ID: 26771081
[TBL] [Abstract][Full Text] [Related]
18. Anterior ventral tegmental area dopaminergic neurons are not involved in the motivational effects of bromocriptine, pramipexole and cocaine in drug-free rats.
Ouachikh O; Dieb W; Durif F; Hafidi A
Behav Brain Res; 2014 Apr; 262():1-7. PubMed ID: 24361908
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease.
Jiménez-Urbieta H; Gago B; Quiroga-Varela A; Rodríguez-Chinchilla T; Merino-Galán L; Oregi A; Belloso-Iguerategui A; Delgado-Alvarado M; Navalpotro-Gómez I; Marin C; Fernagut PO; Rodríguez-Oroz MC
Neurobiol Aging; 2019 Mar; 75():126-135. PubMed ID: 30572183
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
